<DOC>
	<DOCNO>NCT00006041</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety immunization glycosylated MUC-1-KLH vaccine plus adjuvant QS21 patient ovarian , fallopian tube , peritoneal epithelial cancer . II . Determine dose treatment regimen optimal antibody response patient . III . Determine effect immunization treatment regimen T-cell response patient . OUTLINE : This dose escalation study glycosylated MUC-1-KLH vaccine . Patients receive glycosylated MUC-1-KLH vaccine QS21 subcutaneously week week 1-3 , 7 , 19 . Cohorts 6 patient receive escalate dos glycosylated MUC-1-KLH dose optimal antibody response without unacceptable toxicity determine . Patients follow 2 12 week , every 3 month thereafter long detectable immunity MUC-1 persists . PROJECTED ACCRUAL : A total 18-24 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian , fallopian tube , peritoneal epithelial cancer ( stage diagnosis ) Prior cytoreductive surgery require Refractory recurrent least one prior regimen platinum base chemotherapy No evidence disease follow salvage chemotherapy , define : CA125 le 35 unit Negative physical examination No evidence disease CT scan abdomen pelvis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin , SGOT , alkaline phosphatase less 2 time normal Renal : Creatinine le 1.6 mg/dL Creatinine clearance least 50 mL/min Other : No concurrent active invasive malignancy No seafood allergy No positive stool guaiac ( exclude hemorrhoid ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>